Scientists solve key piece of prostate cancer puzzle

August 14, 2012

Cancer Research UK scientists have revealed a completely new route by which male androgen hormones fuel the growth of prostate cancer, raising the prospect that existing drugs could be used to treat the disease.

Prostate cancers are often treated with hormone therapies that target the (AR) – a large protein that switches on signals telling the cell to divide, and which can become overactive in prostate cancer cells.

AR relies on interactions with several other proteins, such as HSP90 and p23, which help fold it into its active form.

Previously it was thought that p23 and HSP90 work together to activate AR, but this latest research – funded by Cancer Research UK and the Association for International Cancer Research – shows that p23 also increases activity of the AR independently.

Crucially this means that drugs to block p23 could be effective at treating prostate cancers that have become resistant to HSP90 inhibitors – which are currently being trialled in breast and prostate cancers.

The findings are published in Molecular Endocrinology.

Study leader, Dr Charlotte Bevan, from the Department of Surgery and Cancer at Imperial College London, said: “Cell signals from the androgen receptor (AR) drive many prostate cancers and our team is part of an ongoing international effort to find new targets that can potentially disable this key protein.

“Previously it was thought that HSP90 and p23 went hand in hand, so we were surprised to find that p23 was also able to boost the activity of the androgen receptor even when we used a modified form that was unable to bind HSP90.

“Excitingly, drugs that block p23 such as Celastrol, which is derived from a plant used in Chinese medicine, have shown early promise in treating several diseases, such as arthritis and asthma, meaning this research is already a step closer to the clinic. The next stage will be to test the effects of such drugs on prostate cancer cells in the lab.”

The researchers used antibodies specifically designed to target p23 to show that levels of the protein are higher in the nucleus of prostate cancer cells compared to normal cells. They also used a modified form of p23, unable to bind HSP90, to show that p23 can act independently of HSP90 and does not necessarily need the protein to interact with the AR.

Dr Julie Sharp, senior science information manager at Cancer Research UK, said: “These results provide an alternative route by which scientists could potentially target prostate cancer by halting AR activity. What’s more, p23 has a much more defined role in the cell than HSP90, meaning that drugs that target it could potentially have fewer side effects for patients than HSP90 inhibitors. We hope these findings will lead to better treatment options for men with .”

Explore further: Researchers discover that same gene has opposite effects in prostate, breast cancers

More information: Molecular Endocrinology June 28, 2012 me.2011-1360 doi: 10.1210/me.2011-1360

Related Stories

Researchers discover that same gene has opposite effects in prostate, breast cancers

October 17, 2011
Researchers at Cleveland Clinic have discovered that a gene – known as an androgen receptor (AR) – is found in both prostate and breast cancers yet has opposite effects on these diseases.

Study identifies new prostate cancer drug target

February 6, 2012
Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published ...

A single therapy slows multiple cancers

January 23, 2012
Targeting a single protein can help fight both breast cancers and leukemias, according to two reports published online on January 23 in the Journal of Experimental Medicine.

Prostate cancer gets around hormone therapy by activating a survival cell signaling pathway

June 14, 2011
Cancer is crafty. When one avenue driving its growth is blocked by drugs targeting that path, the malignancy often creates a detour, finding an alternative route to get around the roadblock.

Recommended for you

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.